China SXT Pharmaceuticals Reports H1 2023 Financials
Ticker: SXTC · Form: 6-K · Filed: Apr 5, 2024 · CIK: 1723980
| Field | Detail |
|---|---|
| Company | China Sxt Pharmaceuticals, Inc. (SXTC) |
| Form Type | 6-K |
| Filed Date | Apr 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 6-K, foreign-private-issuer
TL;DR
SXT just dropped its Sept 2023 financials via 6-K, check it out.
AI Summary
China SXT Pharmaceuticals, Inc. filed a Form 6-K on April 5, 2024, to report its unaudited condensed consolidated financial results for the six months ended September 30, 2023. The company is a foreign private issuer and will file its annual reports under Form 20-F.
Why It Matters
This filing provides investors with updated financial performance data for China SXT Pharmaceuticals, crucial for assessing the company's operational health and investment potential.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing (6-K) and does not contain new material events or significant financial changes.
Key Numbers
- September 30, 2023 — Financial Period End (The filing provides financial results for the six months ended on this date.)
Key Players & Entities
- China SXT Pharmaceuticals, Inc. (company) — Registrant
- 001-38773 (company) — Commission File Number
- 20230930 (date) — Reporting period end date
- April 5, 2024 (date) — Filing date
FAQ
What type of financial statement is being provided?
The filing provides unaudited condensed consolidated financial statements.
What is the reporting period covered by this filing?
The filing covers the six months ended September 30, 2023.
What form does China SXT Pharmaceuticals use for its annual reports?
China SXT Pharmaceuticals indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of the company?
The principal executive office is located at 178 Taidong Rd North, Taizhou Jiangsu, China.
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 5, 2024.
Filing Stats: 296 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-04-05 09:25:25
Filing Documents
- ea0202804-6k_chinasxt.htm (6-K) — 16KB
- ea020280401ex99-1_china.htm (EX-99.1) — 119KB
- ea020280401ex99-2_china.htm (EX-99.2) — 670KB
- ex99-2_001.jpg (GRAPHIC) — 50KB
- 0001213900-24-030634.txt ( ) — 6248KB
- sxtc-20230930.xsd (EX-101.SCH) — 88KB
- sxtc-20230930_cal.xml (EX-101.CAL) — 42KB
- sxtc-20230930_def.xml (EX-101.DEF) — 335KB
- sxtc-20230930_lab.xml (EX-101.LAB) — 588KB
- sxtc-20230930_pre.xml (EX-101.PRE) — 345KB
- ea0202804-6k_chinasxt_htm.xml (XML) — 736KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 99.2 Unaudited Condensed Consolidated Financial Statements for the Six Months Ended September 30, 2023 and 2022 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: April 4, 2024 China SXT Pharmaceuticals, Inc. By: /s/ Feng Zhou Name: Feng Zhou Title: Chief Executive Officer 3